Monday, February 08, 2021 11:44:13 AM
Yeah with insiders holding hella more than half the outstanding the float here has to be rather smaller-ish. Could get into the $20's sooner than we think!
Recent SMMT News
- Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 • Business Wire • 05/01/2024 11:00:00 AM
- Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024 • Business Wire • 04/24/2024 08:30:00 PM
- Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors • Business Wire • 04/11/2024 08:30:00 PM
- Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum • Business Wire • 04/10/2024 11:00:00 AM
- Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024 • Business Wire • 03/22/2024 11:00:00 AM
- Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024 • Business Wire • 03/14/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 09:05:09 PM
- Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference • Business Wire • 03/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 01:05:51 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/20/2024 12:55:18 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/20/2024 12:32:56 PM
- Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023 • Business Wire • 02/20/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 10:25:38 PM
- Form 5 - Annual statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:35:18 PM
- Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024 • Business Wire • 02/14/2024 03:29:00 PM
- Summit Therapeutics to Host Fourth Quarter & Full Year 2023 • Business Wire • 02/14/2024 12:00:00 PM
- Summit Therapeutics to Present at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference • Business Wire • 02/07/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 02:07:05 PM
- Summit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conference • Business Wire • 01/08/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:33:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:22:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:19:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 09:06:38 PM
- Summit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference • Business Wire • 01/03/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2023 09:49:19 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM